22nd Century Group Overview
- Founded
- 1998
- Status
- Public
- Employees
- 76
- Stock Symbol
- XXII
- Investments
- 4
- Share Price
- $2.09
- (As of Monday Closing)
22nd Century Group General Information
Description
22nd Century Group Inc is a US-based plant biotechnology company. It focuses on developing technology that allows the increase or decrease in the level of nicotine and other nicotinic alkaloids in tobacco plants and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. The company is engaged in the research and development of potentially less harmful or modified risk tobacco products and novel tobacco plant varieties. Other business activities of the company include manufacture, marketing, sales, and distribution of SPECTRUM and VLN proprietary cigarettes, contract manufacturing of third-party branded tobacco products, research and development of plant varieties of hemp/cannabis, the sale of branded proprietary tobaccos, and among others.
Contact Information
Website
www.xxiicentury.com
Formerly Known As
Touchstone Mining
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Other Consumer Non-Durables
Agricultural Chemicals
Stock Exchange
NAS
Primary Office
- 500 Seneca Street
- Suite 507
- Buffalo, NY 14204
- United States
+1 (716) 000-0000
22nd Century Group Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.09 | $2.11 | $1.86 - $6.07 | $344M | 163M | 4.01M | -$0.21 |
22nd Century Group Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 449,995 | 449,995 | 281,059 | 105,964 |
| Revenue | 30,948 | 30,948 | 28,111 | 25,833 |
| EBITDA | (31,322) | (31,322) | (20,006) | (26,143) |
| Net Income | (32,609) | (32,609) | (19,711) | (26,558) |
| Total Assets | 75,954 | 75,954 | 51,694 | 68,951 |
| Total Debt | 2,336 | 2,336 | 786 | 1,475 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
22nd Century Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore 22nd Century Group‘s full profile, request access.
Request a free trial22nd Century Group Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
22nd Century Group Inc is a US-based plant biotechnology company. It focuses on developing technology that allows the in
Biotechnology
Buffalo, NY
76
As of 2021
000.00
000000000
000.00
0000 000
eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
000000000000000
Petach Tikva, Israel
00000
As of 0000
00000
00000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trial22nd Century Group Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 0000 0000000000000 | Corporate Backed or Acquired | Petach Tikva, Israel | 00000 | 00000 | 00000000000 | 00000 |
22nd Century Group Patents
22nd Century Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200140875-A1 | Genome editing methods for producing low-nicotine tobacco products | Pending | 31-May-2017 | 00000000000 | |
| US-20180340180-A1 | Dominant-negative genetic manipulation to make low-nicotine tobacco products | Abandoned | 19-May-2017 | 00000000000 | |
| AU-2017332638-A1 | Trichome specific promoters for the manipulation of cannabinoids and other compounds in glandular trichomes | Pending | 20-Sep-2016 | 00000000000 | |
| US-20210040492-A1 | Trichome specific promoters for the manipulation of cannabinoids and other compounds in grandular trichomes | Pending | 20-Sep-2016 | 00000000000 | |
| US-10787674-B2 | Trichome specific promoters for the manipulation of cannabinoids and other compounds in grandular trichomes | Active | 20-Sep-2016 | C12N15/8223 | 0 |
22nd Century Group Executive Team (7)
22nd Century Group Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Clifford Fleet III | 22nd Century Group | Board Member | 000 0000 |
| James Mish | 22nd Century Group | Chief Executive Officer & Board Member | 000 0000 |
| Nora Sullivan | Self | Chairman & Board Member | 000 0000 |
| Roger O'Brien | 22nd Century Group | Board Member | 000 0000 |
22nd Century Group Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial22nd Century Group Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 0000 | 03-Dec-2019 | 000000000 | 000.00 | Drug Discovery | 00000000 |
| 00000000 0000 | 23-Dec-2014 | 000000000 | 00.000 | Buildings and Property | 00000 000 |
| 0000000 | 18-Sep-2014 | 000000000 | 00.00 | Biotechnology | 000000 00 |
| Nasco Products | 29-Aug-2014 | Merger/Acquisition | 00.00 | Other Consumer Non-Durables | 000000 00 |
22nd Century Group Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 0000 00000 | 03-Dec-2019 | 000000000 | 000.00 | Completed |
|
| Anandia | 18-Sep-2014 | Corporate | 00.00 | Completed |